Sun Yat-sen University: all 1,680 studies

Page 5 of 17. Open to participants first (609), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingNCT06054191Phase 2
• Effect of Health Education on Promoting Influenza Vaccination Health LiteracyRecruitingNCT06048406Not applicable
• Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer PatientsRecruitingNCT06043999Not applicable
• Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCRecruitingNCT06041477Phase 3
• Utilization of Transanal Endoscopy in the Treatment of Anastomotic StenosisRecruitingNCT06036862Not applicable
• Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep LearningRecruitingNCT06032767
• Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical TrialRecruitingNCT06031285Phase 2
• Submucosal Saline Injection Followed by Endoscopic UltrasoundRecruitingNCT06022978Not applicable
• The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.RecruitingNCT06019455
• Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyRecruitingNCT06018714Phase 2
• Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine TumorsRecruitingNCT06015802
• Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal CancerRecruitingNCT06014372Phase 2
• Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaRecruitingNCT06013618Phase 2
• Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLCRecruitingNCT05997719
• A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR VariantNot yet recruitingNCT05997459Phase 2
• Neoadjuvant Toripalimab for dMMR/MSI-H Gastric CancerRecruitingNCT05994456Phase 2
• Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)Not yet recruitingNCT05988372Phase 2
• The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal CancerRecruitingNCT05984485Phase 3
• Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal CancerRecruitingNCT05980689Phase 2
• Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in LymphomaNot yet recruitingNCT05969158Phase 2
• Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant RadiotherapyRecruitingNCT05965531Phase 2
• Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapyRecruitingNCT05962502Phase 2
• Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingNCT05959356Phase 2
• Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
• Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin LymphomaRecruitingNCT05949931Phase 2
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPCRecruitingNCT05941741Phase 3
• Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal CancerRecruitingNCT05933980Phase 2
• Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
• Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaRecruitingNCT05930665Phase 2
• Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Phase 3
• Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05913414Phase 2
• A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingNCT05900765Phase 2
• Construction and Validation of Risk Prediction Model for Gastrointestinal Dysfunction of Patient With Colorectal CancerRecruitingNCT05891301
• HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
• TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingNCT05883176Phase 2
• Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT05877872Phase 3
• HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCCRecruitingNCT05866172Phase 3
• Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Phase 3
• Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)RecruitingNCT05848102Phase 4
• Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT05847764Phase 2
• The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive AgeRecruitingNCT05838157
• The Investigation of Knowledge and Educational Demand of Sexual and Reproductive Health Among Cancer SurvivorsNot yet recruitingNCT05817981
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver MetastasesRecruitingNCT05794971Phase 3
• The Efficacy and Safety of Rifaximin TreatmentRecruitingNCT05786859Early Phase 1
• A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPCNot yet recruitingNCT05780294Phase 3
• Evaluation of COVID-19 Immune Barrier and Reinfection RiskRecruitingNCT05774093
• Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRCRecruitingNCT05768503Phase 3
• Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesRecruitingNCT05768490Phase 3
• Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell CarcinomaRecruitingNCT05760053Phase 2
• Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialRecruitingNCT05751343Phase 2
• PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCCRecruitingNCT05737563Phase 3
• A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.RecruitingNCT05731336
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM PatientsRecruitingNCT05727163Phase 2
• Safety and Efficacy of Two-step Radical ProstatectomyRecruitingNCT05722392
• A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic AgentsRecruitingNCT05718492Not applicable
• SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)Not yet recruitingNCT05718232Phase 3
• Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and SubtypesRecruitingNCT05635435
• Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCCRecruitingNCT05626569Phase 2
• Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingNCT05623267Phase 2/3
• Explainable Ocular Fundus Diseases Report Generation SystemRecruitingNCT05622565
• A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and ChemotherapyNot yet recruitingNCT05622474Not applicable
• Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05609695
• A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM MultiformeRecruitingNCT05600491Phase 3
• Influence and Mechanism of Dyadic Coping on Parenting Stress and Parenting Self-Efficacy in Parents of Preterm InfantRecruitingNCT05592210
• RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal CancerRecruitingNCT05578287Phase 2
• Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingNCT05577364Phase 1/2
• Safety and Efficacy of RX-af01 Combined With PD-1 AntibodyRecruitingNCT05576961Phase 1/2
• Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282
• Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT05572983Phase 2
• Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal CancerRecruitingNCT05571644Phase 2
• Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
• Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for SurveillanceRecruitingNCT05528783
• Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）RecruitingNCT05512520Phase 2
• A Big Data-based Cohort Study for Cataract PatientsRecruitingNCT05491798
• HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority StudyRecruitingNCT05476432Phase 3
• Minocycline Treatment for Cystoid Macular EdemaRecruitingNCT05474950Phase 1/2
• Minocycline for Chronic Autoimmune UveitisRecruitingNCT05474729Phase 1/2
• Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation TherapyRecruitingNCT05468242Phase 2
• Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudyRecruitingNCT05457829Phase 2
• Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma ScreeningRecruitingNCT05447169
• Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNCT05444478Not applicable
• A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPCNot yet recruitingNCT05433597Phase 2/3
• Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05431764Phase 2
• Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT05430399Phase 3
• Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter StudyNot yet recruitingNCT05417139Phase 2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
• Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.RecruitingNCT05397769Phase 2
• Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
• Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III TrialRecruitingNCT05367206Phase 3
• Effect of Prebiotics on Blood Pressure ManagementNot yet recruitingNCT05364736Not applicable
• PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)RecruitingNCT05357846Phase 3
• Preoperative Systemic Therapy for Colorectal Cancer Peritoneal MetastasesNot yet recruitingNCT05353582Phase 2
• Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal CarcinomaRecruitingNCT05352321Not applicable
• Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal CarcinomaRecruitingNCT05342792Phase 3
• PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT05341193Phase 1/2
• Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Phase 3
• Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear AcceleratorEnrolling by invitationNCT05338866
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationRecruitingNCT05313282Phase 3

← Sun Yat-sen University overview and focus areas